X


See our webpage about the GA-map® product platform

 

Visit page
Skip to content
Genetic Analysis
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Subsequent Offering 2025
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Mailing List
  • Contact us
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Subsequent Offering 2025
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Mailing List
  • Contact us

News

Genetic Analysis: Direct issue has now been registered with the Norwegian Register of Business Enterprises

2025-06-18

Genetic Analysis announces preliminary outcome of the subsequent offering to existing shareholders

2025-06-182025-06-16

Genetic Analysis AS: Mandatory notification of trade

2025-06-182025-06-12

Today is the last day for trading in the subscription rights for subscribing for shares in Genetic Analysis

2025-06-12

Today the subscription period in Genetic Analysis subsequent offering begins

2025-06-052025-06-05

Genetic Analysis first day of trading excluding subscription rights

2025-06-042025-06-03

Genetic Analysis publishes Simplified disclosure document relating to the previously announced subsequent offering

2025-06-02

Genetic Analysis Last day of trading including subscription rights

2025-06-022025-06-02

Genetic Analysis announces details of Subsequent Offering following directed issue

2025-06-022025-05-27

Publication of Q1 report January – March 2025

2025-05-272025-05-27
Post navigation
Older posts
Page1 Page2 … Page8 Next →

Genetic Analysis AS is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Contact

Phone: +47 48 32 16 10
E-mail: info@genetic-analysis.com
Address: Genetic Analysis AS, Ulvenveien 80B
0581 Oslo, Norway

Open Google Maps
Connect

LinkedIn

Facebook

Twitter

Navigate

Contact Us

Terms of Use

Privacy Policy

© 2023 Genetic Analysis

  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Subsequent Offering 2025
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Mailing List
  • Contact us